ADC Therapeutics SA reports results for the quarter ended in December - Earnings Summary

ADC Therapeutics SA

28/02/2023 13:31

* ADC Therapeutics SA  ADCT.N  reported a quarterly adjusted
loss
of 30 cents​​ per share for the quarter ended in December. The
mean expectation of eight analysts for the quarter was for a
loss of 29 cents per share.
    * Revenue rose 310.3% to $69.80 million from a year ago;
analysts
expected $65.49 million. 
    * ADC Therapeutics SA's reported EPS for the quarter was a
loss
of 30 cents​.
    * The mean earnings estimate of analysts had risen by
about 4.4%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * ADC Therapeutics SA shares had risen by 6.0% this quarter.
    * The company reported a quarterly loss of $24.16 million.
    * Wall Street's median 12-month price target for ADC
Therapeutics
SA is $12.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
28 at 01:31 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.29          -0.30          Missed
 Sep. 30 2022      -0.35          -0.65          Missed
 Jun. 30 2022      -0.91          -0.84          Beat
 Mar. 31 2022      -0.70          -0.22          Beat